钆延迟增强的范围与特征对活检证实结节病患者心律失常风险的分层作用
研究纳入324例活检证实的结节病患者,分析心脏磁共振钆延迟增强(LGE)的范围、模式和位置对室性心动过速/心室颤动/适当器械治疗(主要终点)、心衰住院/心脏移植及全因死亡的预测价值。中位随访4.6年,30例(9.3%)达主要终点;LGE范围独立预测主要终点(每SD变化HR 1.03,95%CI 1.00-1.06,P=0.047),右室间隔、右室游离壁及多灶性LGE强烈预测心律失常终点。作者据此提出4组风险分层算法,累积事件率分别为1%、11%、23%、44%,较心脏节律学会分类系统显著改善模型性能与风险区分度。
要点
- 活检证实结节病患者中,右室间隔LGE(HR 5.43)、右室游离壁LGE(HR 4.30)及多灶性LGE(HR 4.62)强烈预测室性心律失常终点。
- LGE范围每增加1个SD,主要终点风险HR 1.03(95%CI 1.00-1.06,P=0.047),但对心衰住院/心脏移植及全因死亡无独立预测价值。
- 基于LGE特征提出的4组分层算法累积事件率分别为1%、11%、23%、44%(卡方=44.7,P=1.084×10⁻⁹),较HRS分类系统风险区分度提高(ΔAUC=0.082,P=0.019)。
核心结论
- 作者提出基于LGE特征的新风险分层方法,用于评估活检证实结节病患者危及生命的室性心律失常风险。
研究设计与样本
- 研究队列纳入324例活检证实的结节病患者,分析LGE范围、模式和位置,主要终点为室性心动过速或心室颤动或适当器械治疗,次要终点为心衰住院或心脏移植及全因死亡,随访4.6年。
关键影像表现/征象
- 右室间隔LGE(HR 5.43,95%CI 2.61-11.30,P<0.001)、右室游离壁LGE(HR 4.30,95%CI 1.99-9.27,P<0.001)及多灶性LGE(HR 4.62,95%CI 2.19-9.72,P<0.001)强烈预测心律失常终点。
- LGE范围独立预测主要终点(每SD变化HR 1.03,95%CI 1.00-1.06,P=0.047),但对心衰住院/心脏移植(P=0.30)及全因死亡(P=0.50)无独立预测价值。
诊断标准与关键数值
- 基于LGE特征提出的算法识别4个患者亚组,累积事件率分别为1%、11%、23%和44%(卡方=44.7,P=1.084×10⁻⁹)。
- 与心脏节律学会分类系统相比,该算法显著改善模型性能(卡方=8.02,P=0.046)和风险区分度(ΔAUC=0.082,P=0.019),并重新分类43%的人群(9%升至更高风险类别,34%降至更低风险类别)。
临床应用与阅片要点
- 在活检证实结节病患者中,评估LGE时应关注右室间隔、右室游离壁及多灶性分布,这些特征与室性心律失常风险强烈相关。
- LGE范围每增加1个SD,室性心律失常风险HR 1.03(95%CI 1.00-1.06),但原文未报告具体SD数值。
- 作者提出的4组风险分层算法可用于识别高危患者,累积事件率从1%至44%递增。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Risk assessment in cardiac sarcoidosis remains challenging.
OBJECTIVES: This study explored the prognostic value of myocardial late gadolinium enhancement (LGE) in sarcoidosis patients.
METHODS: The study cohort included 324 patients with biopsy-proven sarcoidosis. LGE extent, pattern, and location were analyzed. The primary endpoint was ventricular tachycardia (VT) or ventricular fibrillation (VF) or appropriate device therapy. Secondary endpoints were hospitalization for heart failure (HF) or heart transplantation (HTx) and all-cause mortality.
RESULTS: Over a 4.6-year follow-up, 30 patients (9.3%) reached the primary endpoint. HF/HTx occurred in 15 patients (4.6%) and all-cause mortality in 41 (12.7%). LGE extent was independently predictive of the primary endpoint (per SD change: HR: 1.03 [95% CI: 1.00-1.06]; P = 0.047), but not of HF/HTx (P = 0.30) or all-cause mortality (P = 0.50). Further to LGE extent, LGE on the right ventricular (RV) septum (HR: 5.43 [95% CI: 2.61-11.30]; P < 0.001), RV free wall (HR: 4.30 [95% CI: 1.99-9.27]; P < 0.001), and multifocal LGE (HR: 4.62 [95% CI: 2.19-9.72]; P < 0.001) were strongly predictive of the arrhythmia endpoint. Based on these findings, we propose an algorithm that identifies 4 patient subgroups and stratifies well the arrhythmia risk in biopsy-proven sarcoidosis patients (cumulative event rates: 1%, 11%, 23%, and 44%, respectively; chi-square = 44.7; P = 1.084 × 10-9). Compared with the Heart Rhythm Society classification system, this approach significantly enhanced model performance (chi-square = 8.02; P = 0.046) and risk discrimination (ΔAUC = 0.082; P = 0.019), and reclassified 43% of the population (9% to higher and 34% to lower risk categories).
CONCLUSIONS: The authors propose a new risk stratification approach based on LGE features for assessing the risk of life-threatening ventricular arrhythmias in patients with biopsy-proven sarcoidosis.
引用
- Azzu A, Antonopoulos AS, Okafor J, et al. Extent and Features of Late Gadolinium Enhancement Stratify Arrhythmic Risk in Patients With Biopsy-Proven Sarcoidosis. JACC Cardiovasc Imaging. 2025. PMID: 40634021. doi:10.1016/j.jcmg.2025.02.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。